The global pneumatic nebulizers market size was estimated to be USD 0.764 billion in 2023 and is expected to reach at USD 1.52 billion by 2034 with a CAGR of 6.45% during the forecast period 2024-2034. Rising incidence of chronic respiratory diseases, surge in demand for home healthcare devices, growing geriatric population, the convenient accessibility of compact pneumatic nebulizers designed for use at home, increasing technological innovations in these devices aimed at reducing noise production and enhancing their functionality, rising research & development activities, and surge in partnerships & collaborations within market players for the development of new nebulizers are some of the key factors boosting the market growth.
Surge in partnerships & collaborations within market players for the development of new nebulizers is predicted to boost the market growth during the forecast period. A pneumatic nebulizer is a type of nebulizer that administers medication in the form of a spray, primarily utilized to manage respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Patients prefer this device for several reasons, including its versatility in delivering different types of medications, cost-effectiveness, and ease of operation. For instance, in July 2022, Ziccum has selected TEKCELEO, an innovative mechatronic manufacturer with extensive expertise in nebulizers, to collaborate on the development of its new nebulizer. This component is a vital part of enhancing the drying capabilities and scaling up Ziccum's LaminarPace system, which transforms vaccines into thermostable powders, eliminating the need for cold chain transportation.
By product, breath-actuated was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023 owing to the increasing launch of advanced inhalation therapy and growing approvals by regulatory bosies. For instance, in January 2023, The Food and Drug Administration (FDA) has granted clearance to AstraZeneca Plc for the release of its Airsupra inhaler in the United States. This inhaler is designed to aid in the treatment and prevention of bronchoconstriction. Notably, it is the first metered-dose inhaler to offer a specific combination of doses. Additionally, vented is predicted to grow at fastest CAGR during the forecast period owing to the rising focusing on developing innovative products and surge in introduction of new products.
By application, chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023 owing to the growing prevalence of COPD and increasing research & development activities. For instance, in January 2022, Theravance Biopharma, Inc. has reported the enrollment of the initial patient in a Phase 4 study of YUPELRI (revefenacin) inhalation solution. YUPELRI is the sole once-daily, nebulized bronchodilator approved in the United States for the ongoing treatment of individuals with chronic obstructive pulmonary disease (COPD). Additionally, asthma is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of asthma and increasing pace of technological advancements.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023. Hospitals play a crucial role in the healthcare sector and represent a significant revenue stream for the industry as a whole. As a result, numerous companies allocate considerable resources, both in terms of marketing strategies and revenue, to promote their products and services within hospital settings. For instance, in May 2023, PARI, a company specializing in medical devices and pharmaceuticals related to respiratory and inhalation, has revealed its acquisition of the Irish company Nortev. Nortev is known for manufacturing and distributing the equine nebulizer Flexineb, a device used for respiratory therapy in horses through the nebulization of medication or saline. Additionally, home healthcare is predicted to grow at fastest CAGR during the forecast period owing to the ready availability of compact nebulizers suitable for home use, rising technological advancements aimed at enhancing their functionality, growing geriatric population, and increasing launch of new nebulizer.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing geriatric population, surge in the number of surgeries performed, and growing collaborations within market players. For instance, in October 2022, AeroRx Therapeutics is collaborating with HCmed Innovations to create a novel therapeutic combination of bronchodilator medications from different classes. These medications are designed to widen the airways, facilitating easier breathing, and are intended for the treatment of individuals with chronic obstructive pulmonary disease (COPD). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing burden of COPD, and increasing launch of new facilities in healthcare products. For instance, in February 2023, Berry Global Group has unveiled its plans to set up a new manufacturing facility and healthcare center in Bangalore, India, named "Silicon Valley." This initiative aims to enhance global accessibility to healthcare products and the company's research and development solutions. The R&D center has also announced the launch of various healthcare products in 2023, including Dry Powder Inhalers (DPI), plastic caps, and closures.
Surge in partnerships & collaborations within market players for the development of new nebulizers is predicted to boost the market growth during the forecast period. A pneumatic nebulizer is a type of nebulizer that administers medication in the form of a spray, primarily utilized to manage respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Patients prefer this device for several reasons, including its versatility in delivering different types of medications, cost-effectiveness, and ease of operation. For instance, in July 2022, Ziccum has selected TEKCELEO, an innovative mechatronic manufacturer with extensive expertise in nebulizers, to collaborate on the development of its new nebulizer. This component is a vital part of enhancing the drying capabilities and scaling up Ziccum's LaminarPace system, which transforms vaccines into thermostable powders, eliminating the need for cold chain transportation.
By product, breath-actuated was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023 owing to the increasing launch of advanced inhalation therapy and growing approvals by regulatory bosies. For instance, in January 2023, The Food and Drug Administration (FDA) has granted clearance to AstraZeneca Plc for the release of its Airsupra inhaler in the United States. This inhaler is designed to aid in the treatment and prevention of bronchoconstriction. Notably, it is the first metered-dose inhaler to offer a specific combination of doses. Additionally, vented is predicted to grow at fastest CAGR during the forecast period owing to the rising focusing on developing innovative products and surge in introduction of new products.
By application, chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023 owing to the growing prevalence of COPD and increasing research & development activities. For instance, in January 2022, Theravance Biopharma, Inc. has reported the enrollment of the initial patient in a Phase 4 study of YUPELRI (revefenacin) inhalation solution. YUPELRI is the sole once-daily, nebulized bronchodilator approved in the United States for the ongoing treatment of individuals with chronic obstructive pulmonary disease (COPD). Additionally, asthma is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of asthma and increasing pace of technological advancements.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global pneumatic nebulizers market in 2023. Hospitals play a crucial role in the healthcare sector and represent a significant revenue stream for the industry as a whole. As a result, numerous companies allocate considerable resources, both in terms of marketing strategies and revenue, to promote their products and services within hospital settings. For instance, in May 2023, PARI, a company specializing in medical devices and pharmaceuticals related to respiratory and inhalation, has revealed its acquisition of the Irish company Nortev. Nortev is known for manufacturing and distributing the equine nebulizer Flexineb, a device used for respiratory therapy in horses through the nebulization of medication or saline. Additionally, home healthcare is predicted to grow at fastest CAGR during the forecast period owing to the ready availability of compact nebulizers suitable for home use, rising technological advancements aimed at enhancing their functionality, growing geriatric population, and increasing launch of new nebulizer.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing geriatric population, surge in the number of surgeries performed, and growing collaborations within market players. For instance, in October 2022, AeroRx Therapeutics is collaborating with HCmed Innovations to create a novel therapeutic combination of bronchodilator medications from different classes. These medications are designed to widen the airways, facilitating easier breathing, and are intended for the treatment of individuals with chronic obstructive pulmonary disease (COPD). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing burden of COPD, and increasing launch of new facilities in healthcare products. For instance, in February 2023, Berry Global Group has unveiled its plans to set up a new manufacturing facility and healthcare center in Bangalore, India, named "Silicon Valley." This initiative aims to enhance global accessibility to healthcare products and the company's research and development solutions. The R&D center has also announced the launch of various healthcare products in 2023, including Dry Powder Inhalers (DPI), plastic caps, and closures.
Segmentation: Pneumatic Nebulizers Market Report 2023 - 2034
Pneumatic Nebulizers Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Vented Nebulizer
- Breath-actuated Nebulizer
Pneumatic Nebulizers Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Others
Pneumatic Nebulizers Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home Healthcare
- Hospitals & Clinics
Pneumatic Nebulizers Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Pneumatic Nebulizers Market: Product Estimates & Trend Analysis
8. Pneumatic Nebulizers Market: Application Estimates & Trend Analysis
9. Pneumatic Nebulizers Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Pneumatic Nebulizers Market
12. Europe Global Pneumatic Nebulizers Market
13. Asia Pacific Global Pneumatic Nebulizers Market
14. Latin America Global Pneumatic Nebulizers Market
15. MEA Global Pneumatic Nebulizers Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- PARI GmbH
- BD (Becton
- Dickinson & Company)
- OMRON Corporation
- Medline Industries LP
- Koninklijke Philips N.V.
- General Electric
- Briggs Healthcare
- Vectura Group Ltd
- GF Health Products Inc.
- Allied Healthcare Products Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.76 Billion |
| Forecasted Market Value ( USD | $ 1.52 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
